Symptomatic effect and serum gastrin level after treatment with proton pump inhibitor in GERD investigation in partial responder to potassium-competitive acid blocker

Symptomatic effect and serum gastrin level after treatment with proton pump inhibitor in GERD investigation in partial responder to potassium-competitive acid blocker - Symptomatic effect and serum gastrin level after treatment with proton pump inhibitor in GERD investigation in partial responder to potassium-competitive acid blocker

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030941

Enrollment

Registered

2018-01-23

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GERD

Interventions

Esomeprazole 20 mg capsule Orally administered once a day for 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patient who gave written consent to study participation by free documentation and verbally enough explanation. 2.Patients aged 20 years and older at 2 years of age 3.Three patients diagnosed as reflux esophagitis. 4. Patients with Pcab resistant reflux esophagitis whose gastrointestinal symptoms remained despite intake of Vonoprazan for 4 weeks or more at the time of registration. 5.Patients with total score of 8 or more in the 5FSSG interview sheet.

Exclusion criteria

Exclusion criteria: (1) Patients with warning findings such as vomiting subject to endoscopic examination, gastrointestinal bleeding (including findings of hematemesis, venous drainage, anemia, etc.), and rapid weight loss. (2) Patients with malignant lesions confirmed or suspected of malignant lesions. (3) A patient with a history of gastrointestinal resection and vagotomy. (4) Patients with irritable bowel syndrome. (5) Patients who are difficult to participate in this study due to mergers of severe liver disease, kidney disease, heart disease etc. (6) Pregnant women, lactating women or lactating women who may be pregnant. (7) Patients who other doctors judged inappropriate as subjects of this study.

Design outcomes

Primary

Measure	Time frame
the change in FSSG total score before and 4 weeks after treatment with Esomeprazole	—

Secondary

Measure	Time frame
1. Score change of each of the reflux score and exercise failure score after 2 or 4 weeks evaluated by the FSSG questionnaire 2. Total core change after 2 weeks evaluated by FSSG questionnaire 3. Therapeutic reactivity after 2 or 4 weeks evaluated in the GOS questionnaire 4. Serum gastrin level change before and after esomeprazole administration 5. tolerability during administration of both drugs	—

Countries

Japan

Contacts

Public ContactShinichi Ishihara

Ishihara Gastroenterology Clinic Gastroenterology

ccy63890@yahoo.co.jp0877-63-6677

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026